In vivo self-assembly induced retention of gold nanoparticles for enhanced photothermal tumor treatment

Hu, Xuefeng; Yang, Peipei; He, Jie; Liang, Ruijie; Niu, Dechao; Wang, Hao; Li, Yongsheng

doi:10.1039/c7tb01268c

Cited by 25 publications

(22 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, finding a simple and controllable strategy to enable small-sized nanoparticles to selectively aggregate at tumor sites has become a crucial issue in the field of nanomedicines. 7,8 For instance, nanoparticles are designed to show impaired colloidal stability in the acidic environment at the tumor site to drive agglomeration. 9 Alternatively, nanoparticles are modified by stimuli-responsive peptides 10,11 or polymers, 12,13 which can be cross-linked or cleaved (changing the solubility) by tumor-specific enzymes or molecules, and, as a result, noncovalent self-assembly or covalent cross-linking of nanoparticles was induced into the tumor site.…”

Section: Introductionmentioning

confidence: 99%

Robust and Tumor-Environment-Activated DNA Cross-Linker Driving Nanoparticle Accumulation for Enhanced Therapeutics

Zhang

Fan

et al. 2020

CCS Chem

View full text Add to dashboard Cite

Agglomeration of therapeutic nanoparticles in response to tumor microenvironments is a promising approach to enhance drug accumulation and improve therapeutic efficacy. Cytosine-rich DNA sequences show potential as ideal cross-linkers to drive nanoparticle agglomeration because they can sensitively respond to weak acidity and form interchain folding. However, the in vivo application of DNA is generally limited by its poor biostability; as a consequence, modifications with unprotected DNA cross-linkers can enhance the accumulation of nanoparticles twofold at the tumor site. Facing this challenge, we have designed and developed a protection and tumor-environment activation strategy to enable the in vivo application of a DNA cross-linker. Specifically, reactive oxygen species (ROS)-responsive polyethylene glycol (PEG) was modified on the nanoparticle surface together with the DNA crosslinker, which protects DNA from degradation during the blood circulation; meanwhile, when arriving at the tumor site, the nanoparticles shed the PEG shell as a response to ROS to uncover and activate the DNA cross-linkers. Using this strategy, a sevenfold enhancement in tumor accumulation was achieved owing to both superior pH sensitivity and improved stability of DNA cross-linkers. Finally, significantly improved therapeutic efficacy in in vivo anticancer treatment was realized by using this agglomeration strategy driven by protected and stimuli-activated DNA cross-linkers.

show abstract

Section: Introductionmentioning

confidence: 99%

Robust and Tumor-Environment-Activated DNA Cross-Linker Driving Nanoparticle Accumulation for Enhanced Therapeutics

Zhang

Fan

et al. 2020

CCS Chem

View full text Add to dashboard Cite

show abstract

“…[2,9] Although several nanoplatforms have been built to detect inflammation utilizing polymers, [5d, 10] liposomes, [5c] carbon nanotubes (SWNTs), [11] and magnetic nanoparticles, [12] they tend to be uptaken by the reticuloendothelial system (RES) and accumulate mainly in liver due to their large size (greater than 10 nm), resulting in high background signals and concerns regarding long-term cytotoxicity. [13] To achieve both high SNR and rapid excretion, an ideal contrast agent should have improved delivery efficiency at inflamed tissues and rapid excretion from healthy organs.O ne possible solution to improving the delivery efficiency of contrast agents is using in vivo nanoparticle cross-linking,i ncluding covalent bonding, [14] hydrogen bonding, [15] biotin-avidin recognition, [16] and supramolecular recognition. [17] However,u npredictable cross-linking in blood, RES,a nd normal tissues would also cause high background signals and possible long-term cytotoxicity.…”

mentioning

confidence: 99%

Precise In Vivo Inflammation Imaging Using In Situ Responsive Cross‐linking of Glutathione‐Modified Ultra‐Small NIR‐II Lanthanide Nanoparticles

et al. 2019

View full text Add to dashboard Cite

To improve the bioimaging signal-to-noise ratio (SNR), long-term imaging capability,a nd decrease the potential biotoxicity,aninvivo cross-linking strategy was developed by using sub-10 nm, glutathione-modified, lanthanide nanoprobes.A fter administration, the nanoprobes cross-link in response to reactive oxygen species (ROS) at the inflamed area and enable the quicki maging of ROSi nt he second nearinfrared (NIR-II) window.These nanoprobes could be rapidly excreted due to their ultra-small size. This strategy may also be applied to other ultra-small contrast agents for the precise bioimaging by in situ lesion cross-linking.

show abstract

“…22,43 This osteoclast-mediated release of ED-BMPs is a type of dual delivery system. 44 After the release of adsorbed rhBMP-2, dentin degradation and the release of ED-BMPs partially follow the principles of natural bone remodeling proposed by Howard et al as a local ''coupling factor'' pathway linking bone resorption to subsequent bone 29 Enlarged dentinal tubules (ED) were observed. Multiple activated cell layers encapsulated the dentin matrix surface.…”

Section: Osteoclast Activation With Rhbmp-2mentioning

confidence: 82%

Histological Review of Demineralized Dentin Matrix as a Carrier of rhBMP-2

Kim

et al. 2020

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

In 2007, recombinant human bone morphogenetic protein-2 (rhBMP-2) was approved for use in humans at a concentration of 1.5 mg/mL with absorbable collagen sponges as an alternative to autogenous bone grafts for alveolar ridge augmentation, defects associated with extraction sockets, and sinus augmentation. However, the use of supraphysiological doses and the insufficient retention of rhBMP-2, when delivered through collagen sponge, result in dose-dependent side effects related to off-label use. Demineralized dentin matrix (DDM), an osteoinducing bone substrate, has been used as an rhBMP-2 carrier since 1998. In addition, DDM has both microparticle and nanoparticle structures, which do not undergo remodeling, unlike bone. In vitro, DDM is a suitable carrier for BMP-2, with the continued release over 30 days at concentrations sufficient to stimulate osteogenic differentiation. In this review, we discuss the histological outcomes of DDM loaded with rhBMP-2 to highlight the biological functions of exogenous rhBMP-2 associated with the DDM carrier in clinical applications in implant dentistry.Keywords: bone morphogenetic protein, bone substitute, demineralized dentin matrix Impact StatementDemineralized dentin matrix (DDM) has been used as an recombinant human bone morphogenetic protein (rhBMP-2) carrier and osteo-inducing bone substrate to facilitate continued release and stimulate osteogenic differentiation. In this review, we discuss the histological outcomes of DDM loaded with rhBMP-2 in order to highlight the biological functions of exogenous rhBMP-2 associated with the DDM carrier in clinical applications in implant dentistry.

show abstract

In vivo self-assembly induced retention of gold nanoparticles for enhanced photothermal tumor treatment

Abstract: A simple route to fabricate peptide modified spherical gold nanoparticles with enhanced retention performance in tumor sites for improved photothermal treatment.

Cited by 25 publications

References 49 publications

Robust and Tumor-Environment-Activated DNA Cross-Linker Driving Nanoparticle Accumulation for Enhanced Therapeutics

Robust and Tumor-Environment-Activated DNA Cross-Linker Driving Nanoparticle Accumulation for Enhanced Therapeutics

Precise In Vivo Inflammation Imaging Using In Situ Responsive Cross‐linking of Glutathione‐Modified Ultra‐Small NIR‐II Lanthanide Nanoparticles

Histological Review of Demineralized Dentin Matrix as a Carrier of rhBMP-2

Contact Info

Product

Resources

About